Yanhong Deng
Statistician 3Cards
About
Research
Publications
2026
419P 7-y survival in patients (pts) with extended-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo) in the IMpower133 (IMp133) and IMbrella A extension study, including brain (BM) and liver metastases (LM) by SCLC molecular subtype
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Breyer M, De Castro G, Bernabe R, Kim S, Kowalski D, Andric Z, Li H, Deng Y, Nabet B, Srivastava M, Oancea M, Liu S. 419P 7-y survival in patients (pts) with extended-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo) in the IMpower133 (IMp133) and IMbrella A extension study, including brain (BM) and liver metastases (LM) by SCLC molecular subtype. ESMO Open 2026, 11: 106733. DOI: 10.1016/j.esmoop.2026.106733.Peer-Reviewed Original ResearchCamrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
Peng Z, Zhang Y, Xu H, Yang Y, Yang M, Zhang M, Cheng Y, Chen X, Pan Y, Wang F, Li Q, Xu N, Liu L, Gu K, Xiao J, Zhang R, Zhao Q, Chen J, Lin L, Chen Y, Deng Y, Cai S, Bai B, Wang Y, Shen L. Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. The BMJ 2026, 392: e086115. PMID: 41819560, PMCID: PMC12980530, DOI: 10.1136/bmj-2025-086115.Peer-Reviewed Original ResearchConceptsPD-L1-positive populationGastro-oesophageal junction adenocarcinomaHuman epidermal growth factor receptor 2Dose of study drugEpidermal growth factor receptor 2Treatment related adverse eventsPD-L1Junction adenocarcinomaOverall survivalRelated adverse eventsPositive populationOverall populationStudy drugAdverse eventsReceptor 2Eastern Cooperative Oncology Group performance statusAssociated with longer overall survivalProgrammed death-ligand 1Randomised phase 3 trialCombined positive scoreDeath-ligand 1Longer overall survivalPhase 3 trialPeritoneal metastasisTreatment discontinuationValidation of the Ectropion Severity Score in Epidermal Differentiation Disorders
Echeandia-Francis C, Luo A, Jiang X, Ellis K, Mani M, Chen T, Gan G, Deng Y, Choate K. Validation of the Ectropion Severity Score in Epidermal Differentiation Disorders. JAMA Dermatology 2026, 162 PMID: 41779411, PMCID: PMC12961595, DOI: 10.1001/jamadermatol.2025.6166.Peer-Reviewed Original ResearchTrastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Liu T, Luo S, Yuan X, Liu D, Zhou Z, Wang X, Deng Y, Chen J, Liu M, Zhou H, Ren X, Qiu W, Cao Y, Cai S, Dong Y, Zhang Y, Wang W, Liang J, Xu P, Liu H, Zhao K, Fan Y, Dou N, Huang C, Li J. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Journal Of Clinical Oncology 2026, jco2500716. PMID: 41779980, DOI: 10.1200/jco-25-00716.Peer-Reviewed Original ResearchHuman epidermal growth factor receptor 2Treatment-related adverse eventsProgression-free survivalDose-limiting toxicityGastroesophageal junction adenocarcinomaAntibody-drug conjugatesPhase I trialColorectal cancerMedian OSJunction adenocarcinomaOverall survivalI trialGastric cancerHER2-positive colorectal cancerHER2-targeting antibody-drug conjugateEpidermal growth factor receptor 2Median overall survivalAdvanced gastric cancerDose cohortsOpen-labelStandard treatmentAdverse eventsTrastuzumabReceptor 2Patients135 Growth Patterns in Children With Epidermal Differentiation Disorders: A Longitudinal Registry-Based Study
Echeandia-Francis C, Chen T, Mani M, Luo A, Liu W, Patel R, Ossowska L, Gan G, Deng Y, Paller A, Choate K. 135 Growth Patterns in Children With Epidermal Differentiation Disorders: A Longitudinal Registry-Based Study. Journal Of Investigative Dermatology 2026, 146: s30. DOI: 10.1016/s0022-202x(26)00657-3.Peer-Reviewed Original ResearchDifferentiation disordersAutosomal recessive congenital ichthyosisGrowth impairmentLongitudinal growth outcomesPersistent short statureGenetic skin diseasesRegistry-based studyStandard of careSupplemental caloriesNICU admissionBorn pretermCongenital ichthyosisNutritional supportShort statureG-tubeGenetic diagnosisGrowth disordersGrowth outcomesPediatric standardsSkin diseasesImpaired growthDisordersChildrenOne-thirdGrowth patternConsensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer
Yang Z, Xia F, Li J, Jin J, Wang G, Lin G, Li X, Wu A, Zhang T, Zhang W, Xu J, Tao K, Ding P, Li Y, Xu Y, Song Z, Li L, Deng Y, Wan X, Xu R, Zhang Z, Yao H, Zhang Z. Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer. Gut 2026, gutjnl-2025-336979. PMID: 41748160, DOI: 10.1136/gutjnl-2025-336979.Peer-Reviewed Original ResearchLocally Advanced Rectal CancerImmune checkpoint inhibitorsTreatment of locally advanced rectal cancerAdvanced rectal cancerConsensus guidanceCheckpoint inhibitorsRectal cancerClinical trialsOrgan preservation treatment strategiesOrgan-sparing strategiesPostoperative adjuvant therapyOrgan preservation strategiesExpert consensus guidanceSociety of Colorectal SurgeryTreatment decision-makingPerioperative immunotherapyPreoperative immunotherapyRadiation therapyAdjuvant therapyLocal resectionColorectal surgeryPerioperative managementFollow-upTreatment strategiesEfficacy evaluationLong‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
Maxwell M, Deng Y, Chen B, Silveira M, Boyer J, Assis D. Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Alimentary Pharmacology & Therapeutics 2026 PMID: 41705340, DOI: 10.1111/apt.70574.Peer-Reviewed Original ResearchPrimary biliary cholangitisSecond-line therapyPrognostic scoreLong-term cohortUrsodeoxycholic acidLong-term useFenofibrate therapyBiliary cholangitisPatients treated with fenofibrateResponse to UDCAEffective second-line treatmentPrimary biliary cholangitis patientsCohort of PBC patientsUK-PBC scoreSecond-line treatmentElevated liver enzymesUrsodeoxycholic acid therapyRetrospective cohort studyPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaAlkaline phosphataseFenofibrate useCholestatic markersPBC patientsFIB-4ASO Visual Abstract: Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients With Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trials
Zhang T, Shi L, Jian L, Jiang J, Qiu Y, Xie F, Zhang J, Peng H, Zhong L, Chen Y, Zhong Y, Deng Y. ASO Visual Abstract: Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients With Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trials. Annals Of Surgical Oncology 2026, 1-2. PMID: 41688834, DOI: 10.1245/s10434-025-19038-2.Peer-Reviewed Original ResearchClinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics
Edelman E, Deng Y, Dziura J, Nahum-Shani I, Weiss J, Aoun-Barakat L, Bold K, Harsono D, Mistler C, Payne E, Aiudi S, Sigel K, Yager J, Ledgerwood D, Bernstein S. Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics. JAMA Network Open 2026, 9: e2560593. PMID: 41758512, PMCID: PMC12949440, DOI: 10.1001/jamanetworkopen.2025.60593.Peer-Reviewed Original ResearchConceptsNicotine replacement therapyTobacco use disorderRandomized clinical trialsClinical pharmacistsHIV clinicRandomized clinical trial of peopleSmoking cigarettesClinical pharmacist visitsTobacco-related outcomesNicotine replacement therapy groupContingency managementClinical trials of peopleIntention-to-treat principleTreatment strategiesTrials of peopleUse disorderPharmacist visitAdaptive treatment strategiesMain OutcomesWeeks of treatmentStage 1 treatmentSmoking reductionSecondary outcomesPrimary outcomeStage 1Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study.
Xie X, Lin Z, Li W, Xie Y, Zhang J, Hu H, Li S, Zhai X, Shi L, Deng Y. Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study. Journal Of Clinical Oncology 2026, 44: 124-124. DOI: 10.1200/jco.2026.44.2_suppl.124.Peer-Reviewed Original ResearchWild-type metastatic colorectal cancerMetastatic colorectal cancerMaximum tolerated doseDose-limiting toxicityDose-escalation studyColorectal cancerSerum concentrationsFirst-line maintenance treatmentPharmacokinetic parametersSchedule of cetuximabConcentrations of cetuximabQ3w scheduleDose escalationInduction therapyMaintenance therapyPharmacokinetic exposureQ3wSafety profileCetuximabMaintenance treatmentAdverse eventsCapecitabinePharmacokinetic analysisPhase IbPharmacokinetic reference
Academic Achievements & Community Involvement
News
News
- March 02, 2026
Integrating Tobacco Treatment in HIV Care
- May 29, 2024
Renalase May Predict Post-ERCP Pancreatitis
- January 11, 2023
Discoveries & Impact (January 2023)
- June 15, 2021
Pneumocystis Pneumonia Outbreak Chronicled In Clinical Infectious Diseases
Get In Touch
Contacts
Locations
300 George Street
Academic Office
Ste Suite 555
New Haven, CT 06511